Zoetis Inc.
ZTS | NYSE
$82.11
-$7.09 (-7.95%)
At close: Nov 5, 2026, 4:00 PM ET
$81.75
-$0.36 (-0.44%)
After-hours:
Nov 5, 2026, 5:10 PM ET
Company Profile
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Kristin C. Peck | Chief Executive Officer & Director |
| Wetteny N. Joseph | Special Advisor to the CEO |
| Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations |
| James K. Saccaro | Executive VP, CFO & COO |
| Jamie Brannan | Executive Vice President & Chief Commercial Officer |
| Jeannette Ferran Astorga | Executive Vice President of Corporate Affairs & Chief Sustainability Officer |
| Julie A. Fuller | Executive Vice President, Chief Human Resources Officer & Global Operations |
| Keith Sarbaugh | Executive Vice President & Chief Digital and Technology Officer |
| Nick Ashton | Executive Vice President and President of Global Manufacturing & Supply |
| Robert J. Polzer | Scientific Advisor |
| Roxanne Lagano | Executive Vice President, General Counsel & Corporate Secretary |
| Steven Frank | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Aug 24, 2026 | 3 | Filing |
| Aug 11, 2026 | 4 | Filing |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 14, 2026 | 4 | Filing |
Zoetis Inc.
| Country | United States |
| IPO Date | Feb 1, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 14,500 |
| CEO | Kristin C. Peck |
Contact Details
10 Sylvan Way Parsippany,
New Jersey 07054 United States
Stock Details
| Ticker Symbol | ZTS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001555280 |
| CUSIP Number | 98978V103 |
| ISIN Number | US98978V1035 |
| SIC Code | 2834 |
Recent News
- 7 hours ago / zacks.comZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up
- 8 hours ago / reuters.comZoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall
- 8 hours ago / benzinga.comZoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
- 11 hours ago / zacks.comZoetis (ZTS) Reports Q3 Earnings: What Key Metrics Have to Say
- 12 hours ago / zacks.comZoetis (ZTS) Q3 Earnings and Revenues Top Estimates
- 1 day ago / seekingalpha.comZoetis: Near-Term Expectations More Achievable, Long Growth Runway Undervalued
- 2 days ago / zacks.comZoetis Gears Up to Report Q3 Earnings: Here's What to Expect
- 2 days ago / zacks.comInsights Into Zoetis (ZTS) Q3: Wall Street Projections for Key Metrics
- 7 days ago / zacks.comZoetis (ZTS) Ascends While Market Falls: Some Facts to Note
- 13 days ago / zacks.comZoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
Add to Watchlist
Select watchlists to add or remove ZTS